nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A4—Temozolomide—skin cancer	0.0825	0.21	CbGbCtD
Paliperidone—CYP3A4—Imiquimod—skin cancer	0.0825	0.21	CbGbCtD
Paliperidone—CYP2D6—Vemurafenib—skin cancer	0.0711	0.181	CbGbCtD
Paliperidone—CYP3A4—Vismodegib—skin cancer	0.0572	0.145	CbGbCtD
Paliperidone—CYP3A4—Vemurafenib—skin cancer	0.0452	0.115	CbGbCtD
Paliperidone—CYP3A5—Docetaxel—skin cancer	0.0398	0.101	CbGbCtD
Paliperidone—CYP3A4—Docetaxel—skin cancer	0.0155	0.0394	CbGbCtD
Paliperidone—HRH1—nose—skin cancer	0.00806	0.119	CbGeAlD
Paliperidone—DRD1—nerve—skin cancer	0.00495	0.073	CbGeAlD
Paliperidone—HTR2A—hindlimb—skin cancer	0.00317	0.0468	CbGeAlD
Paliperidone—HTR1B—blood vessel—skin cancer	0.00315	0.0465	CbGeAlD
Paliperidone—HTR1D—blood vessel—skin cancer	0.00305	0.045	CbGeAlD
Paliperidone—DRD2—nerve—skin cancer	0.00292	0.0432	CbGeAlD
Paliperidone—HTR2A—appendage—skin cancer	0.00272	0.0402	CbGeAlD
Paliperidone—HTR2A—nerve—skin cancer	0.00193	0.0285	CbGeAlD
Paliperidone—HTR2A—endothelium—skin cancer	0.00164	0.0242	CbGeAlD
Paliperidone—DRD3—head—skin cancer	0.00164	0.0242	CbGeAlD
Paliperidone—ADRA2C—nipple—skin cancer	0.00161	0.0238	CbGeAlD
Paliperidone—HTR1D—connective tissue—skin cancer	0.00156	0.0231	CbGeAlD
Paliperidone—HTR2A—blood vessel—skin cancer	0.00151	0.0224	CbGeAlD
Paliperidone—HRH1—nipple—skin cancer	0.00131	0.0193	CbGeAlD
Paliperidone—ADRA2A—nipple—skin cancer	0.00129	0.019	CbGeAlD
Paliperidone—ADRA1B—head—skin cancer	0.00126	0.0186	CbGeAlD
Paliperidone—DRD1—head—skin cancer	0.00117	0.0173	CbGeAlD
Paliperidone—ADRA1A—epithelium—skin cancer	0.00114	0.0168	CbGeAlD
Paliperidone—HTR1B—female reproductive system—skin cancer	0.00114	0.0168	CbGeAlD
Paliperidone—HTR1D—female reproductive system—skin cancer	0.0011	0.0163	CbGeAlD
Paliperidone—HTR2C—female reproductive system—skin cancer	0.00109	0.0161	CbGeAlD
Paliperidone—HTR2A—neck—skin cancer	0.00108	0.016	CbGeAlD
Paliperidone—HTR1B—head—skin cancer	0.000951	0.014	CbGeAlD
Paliperidone—ADRA2C—mammalian vulva—skin cancer	0.000943	0.0139	CbGeAlD
Paliperidone—HRH1—connective tissue—skin cancer	0.00093	0.0137	CbGeAlD
Paliperidone—HTR1D—head—skin cancer	0.000921	0.0136	CbGeAlD
Paliperidone—ADRA2A—connective tissue—skin cancer	0.000913	0.0135	CbGeAlD
Paliperidone—HTR2C—head—skin cancer	0.000912	0.0135	CbGeAlD
Paliperidone—HRH1—epithelium—skin cancer	0.000883	0.013	CbGeAlD
Paliperidone—ADRA1A—lymphoid tissue—skin cancer	0.000878	0.013	CbGeAlD
Paliperidone—HTR2A—connective tissue—skin cancer	0.000777	0.0115	CbGeAlD
Paliperidone—HTR1A—head—skin cancer	0.000768	0.0113	CbGeAlD
Paliperidone—HRH1—mammalian vulva—skin cancer	0.000766	0.0113	CbGeAlD
Paliperidone—ADRA2A—mammalian vulva—skin cancer	0.000752	0.0111	CbGeAlD
Paliperidone—HTR2A—epithelium—skin cancer	0.000737	0.0109	CbGeAlD
Paliperidone—ADRA1A—head—skin cancer	0.000708	0.0104	CbGeAlD
Paliperidone—DRD2—head—skin cancer	0.000694	0.0102	CbGeAlD
Paliperidone—ADRA2C—head—skin cancer	0.000674	0.00995	CbGeAlD
Paliperidone—HRH1—female reproductive system—skin cancer	0.000656	0.00968	CbGeAlD
Paliperidone—ADRA2A—female reproductive system—skin cancer	0.000644	0.0095	CbGeAlD
Paliperidone—HRH1—head—skin cancer	0.000548	0.00808	CbGeAlD
Paliperidone—HTR2A—female reproductive system—skin cancer	0.000548	0.00808	CbGeAlD
Paliperidone—ADRA2A—head—skin cancer	0.000538	0.00794	CbGeAlD
Paliperidone—Ill-defined disorder—Dactinomycin—skin cancer	0.000529	0.00104	CcSEcCtD
Paliperidone—Anaemia—Dactinomycin—skin cancer	0.000527	0.00103	CcSEcCtD
Paliperidone—Vomiting—Vemurafenib—skin cancer	0.000523	0.00103	CcSEcCtD
Paliperidone—Alopecia—Temozolomide—skin cancer	0.000523	0.00102	CcSEcCtD
Paliperidone—Dry skin—Docetaxel—skin cancer	0.000522	0.00102	CcSEcCtD
Paliperidone—Myalgia—Bleomycin—skin cancer	0.00052	0.00102	CcSEcCtD
Paliperidone—Chest pain—Bleomycin—skin cancer	0.00052	0.00102	CcSEcCtD
Paliperidone—Abdominal pain upper—Docetaxel—skin cancer	0.00052	0.00102	CcSEcCtD
Paliperidone—Orthostatic hypotension—Docetaxel—skin cancer	0.00052	0.00102	CcSEcCtD
Paliperidone—Rash—Vemurafenib—skin cancer	0.000519	0.00102	CcSEcCtD
Paliperidone—Mental disorder—Temozolomide—skin cancer	0.000519	0.00102	CcSEcCtD
Paliperidone—Dermatitis—Vemurafenib—skin cancer	0.000518	0.00102	CcSEcCtD
Paliperidone—Hypersensitivity—Imiquimod—skin cancer	0.000517	0.00101	CcSEcCtD
Paliperidone—Headache—Vemurafenib—skin cancer	0.000515	0.00101	CcSEcCtD
Paliperidone—Erythema—Temozolomide—skin cancer	0.000515	0.00101	CcSEcCtD
Paliperidone—Malnutrition—Temozolomide—skin cancer	0.000515	0.00101	CcSEcCtD
Paliperidone—Breast disorder—Docetaxel—skin cancer	0.000514	0.00101	CcSEcCtD
Paliperidone—Discomfort—Bleomycin—skin cancer	0.000514	0.00101	CcSEcCtD
Paliperidone—Malaise—Dactinomycin—skin cancer	0.000514	0.00101	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000512	0.001	CcSEcCtD
Paliperidone—Leukopenia—Dactinomycin—skin cancer	0.00051	0.000999	CcSEcCtD
Paliperidone—Nasopharyngitis—Docetaxel—skin cancer	0.000509	0.000997	CcSEcCtD
Paliperidone—CYP3A4—female reproductive system—skin cancer	0.000507	0.00748	CbGeAlD
Paliperidone—Dysgeusia—Temozolomide—skin cancer	0.000505	0.000989	CcSEcCtD
Paliperidone—Asthenia—Imiquimod—skin cancer	0.000503	0.000986	CcSEcCtD
Paliperidone—Confusional state—Bleomycin—skin cancer	0.000503	0.000985	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000502	0.000983	CcSEcCtD
Paliperidone—CYP2D6—female reproductive system—skin cancer	0.000499	0.00736	CbGeAlD
Paliperidone—Oedema—Bleomycin—skin cancer	0.000498	0.000977	CcSEcCtD
Paliperidone—Anaphylactic shock—Bleomycin—skin cancer	0.000498	0.000977	CcSEcCtD
Paliperidone—Back pain—Temozolomide—skin cancer	0.000498	0.000977	CcSEcCtD
Paliperidone—Pruritus—Imiquimod—skin cancer	0.000496	0.000973	CcSEcCtD
Paliperidone—Infection—Bleomycin—skin cancer	0.000495	0.00097	CcSEcCtD
Paliperidone—Dysphagia—Docetaxel—skin cancer	0.000492	0.000964	CcSEcCtD
Paliperidone—Nausea—Vemurafenib—skin cancer	0.000489	0.000958	CcSEcCtD
Paliperidone—Thrombocytopenia—Bleomycin—skin cancer	0.000488	0.000956	CcSEcCtD
Paliperidone—Vision blurred—Temozolomide—skin cancer	0.000486	0.000951	CcSEcCtD
Paliperidone—Myalgia—Dactinomycin—skin cancer	0.000485	0.00095	CcSEcCtD
Paliperidone—Tremor—Temozolomide—skin cancer	0.000483	0.000946	CcSEcCtD
Paliperidone—Alopecia—Fluorouracil—skin cancer	0.000482	0.000944	CcSEcCtD
Paliperidone—Diarrhoea—Imiquimod—skin cancer	0.00048	0.000941	CcSEcCtD
Paliperidone—Discomfort—Dactinomycin—skin cancer	0.000479	0.000939	CcSEcCtD
Paliperidone—Ill-defined disorder—Temozolomide—skin cancer	0.000478	0.000937	CcSEcCtD
Paliperidone—Anaemia—Temozolomide—skin cancer	0.000476	0.000933	CcSEcCtD
Paliperidone—Anorexia—Bleomycin—skin cancer	0.000475	0.000931	CcSEcCtD
Paliperidone—Erythema—Fluorouracil—skin cancer	0.000475	0.00093	CcSEcCtD
Paliperidone—Agitation—Temozolomide—skin cancer	0.000473	0.000928	CcSEcCtD
Paliperidone—ADRA2C—lymph node—skin cancer	0.000472	0.00697	CbGeAlD
Paliperidone—Angioedema—Temozolomide—skin cancer	0.000471	0.000923	CcSEcCtD
Paliperidone—Hypotension—Bleomycin—skin cancer	0.000466	0.000913	CcSEcCtD
Paliperidone—Oedema—Dactinomycin—skin cancer	0.000465	0.000911	CcSEcCtD
Paliperidone—Malaise—Temozolomide—skin cancer	0.000465	0.00091	CcSEcCtD
Paliperidone—Dizziness—Imiquimod—skin cancer	0.000464	0.000909	CcSEcCtD
Paliperidone—Vertigo—Temozolomide—skin cancer	0.000463	0.000907	CcSEcCtD
Paliperidone—Infection—Dactinomycin—skin cancer	0.000462	0.000905	CcSEcCtD
Paliperidone—Leukopenia—Temozolomide—skin cancer	0.000461	0.000904	CcSEcCtD
Paliperidone—Neutropenia—Docetaxel—skin cancer	0.00046	0.000901	CcSEcCtD
Paliperidone—HTR2A—head—skin cancer	0.000458	0.00675	CbGeAlD
Paliperidone—Palpitations—Temozolomide—skin cancer	0.000455	0.000892	CcSEcCtD
Paliperidone—Thrombocytopenia—Dactinomycin—skin cancer	0.000455	0.000892	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000454	0.00089	CcSEcCtD
Paliperidone—Cough—Temozolomide—skin cancer	0.00045	0.000881	CcSEcCtD
Paliperidone—Paraesthesia—Bleomycin—skin cancer	0.000448	0.000877	CcSEcCtD
Paliperidone—Weight increased—Docetaxel—skin cancer	0.000448	0.000877	CcSEcCtD
Paliperidone—Vision blurred—Fluorouracil—skin cancer	0.000447	0.000877	CcSEcCtD
Paliperidone—Convulsion—Temozolomide—skin cancer	0.000446	0.000875	CcSEcCtD
Paliperidone—Vomiting—Imiquimod—skin cancer	0.000446	0.000874	CcSEcCtD
Paliperidone—Weight decreased—Docetaxel—skin cancer	0.000445	0.000872	CcSEcCtD
Paliperidone—Hypertension—Temozolomide—skin cancer	0.000445	0.000872	CcSEcCtD
Paliperidone—Dyspnoea—Bleomycin—skin cancer	0.000444	0.000871	CcSEcCtD
Paliperidone—Anorexia—Dactinomycin—skin cancer	0.000443	0.000868	CcSEcCtD
Paliperidone—Rash—Imiquimod—skin cancer	0.000442	0.000867	CcSEcCtD
Paliperidone—Dermatitis—Imiquimod—skin cancer	0.000442	0.000866	CcSEcCtD
Paliperidone—Pneumonia—Docetaxel—skin cancer	0.000441	0.000864	CcSEcCtD
Paliperidone—Headache—Imiquimod—skin cancer	0.00044	0.000861	CcSEcCtD
Paliperidone—Anaemia—Fluorouracil—skin cancer	0.000439	0.00086	CcSEcCtD
Paliperidone—Myalgia—Temozolomide—skin cancer	0.000439	0.00086	CcSEcCtD
Paliperidone—Arthralgia—Temozolomide—skin cancer	0.000439	0.00086	CcSEcCtD
Paliperidone—Infestation—Docetaxel—skin cancer	0.000438	0.000859	CcSEcCtD
Paliperidone—Infestation NOS—Docetaxel—skin cancer	0.000438	0.000859	CcSEcCtD
Paliperidone—Anxiety—Temozolomide—skin cancer	0.000437	0.000857	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000436	0.000854	CcSEcCtD
Paliperidone—Discomfort—Temozolomide—skin cancer	0.000433	0.000849	CcSEcCtD
Paliperidone—Decreased appetite—Bleomycin—skin cancer	0.000433	0.000849	CcSEcCtD
Paliperidone—Dry mouth—Temozolomide—skin cancer	0.000429	0.000841	CcSEcCtD
Paliperidone—Jaundice—Docetaxel—skin cancer	0.000427	0.000837	CcSEcCtD
Paliperidone—Pain—Bleomycin—skin cancer	0.000426	0.000835	CcSEcCtD
Paliperidone—Conjunctivitis—Docetaxel—skin cancer	0.000426	0.000835	CcSEcCtD
Paliperidone—Leukopenia—Fluorouracil—skin cancer	0.000425	0.000833	CcSEcCtD
Paliperidone—Confusional state—Temozolomide—skin cancer	0.000424	0.000831	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000424	0.00083	CcSEcCtD
Paliperidone—Oedema—Temozolomide—skin cancer	0.00042	0.000824	CcSEcCtD
Paliperidone—Anaphylactic shock—Temozolomide—skin cancer	0.00042	0.000824	CcSEcCtD
Paliperidone—Infection—Temozolomide—skin cancer	0.000418	0.000819	CcSEcCtD
Paliperidone—CYP2D6—head—skin cancer	0.000417	0.00615	CbGeAlD
Paliperidone—Nausea—Imiquimod—skin cancer	0.000417	0.000817	CcSEcCtD
Paliperidone—Hepatobiliary disease—Docetaxel—skin cancer	0.000415	0.000813	CcSEcCtD
Paliperidone—Epistaxis—Docetaxel—skin cancer	0.000414	0.00081	CcSEcCtD
Paliperidone—Nervous system disorder—Temozolomide—skin cancer	0.000412	0.000808	CcSEcCtD
Paliperidone—Thrombocytopenia—Temozolomide—skin cancer	0.000412	0.000807	CcSEcCtD
Paliperidone—Convulsion—Fluorouracil—skin cancer	0.000411	0.000806	CcSEcCtD
Paliperidone—Feeling abnormal—Bleomycin—skin cancer	0.000411	0.000805	CcSEcCtD
Paliperidone—Agranulocytosis—Docetaxel—skin cancer	0.000409	0.000802	CcSEcCtD
Paliperidone—Skin disorder—Temozolomide—skin cancer	0.000408	0.0008	CcSEcCtD
Paliperidone—Chest pain—Fluorouracil—skin cancer	0.000404	0.000792	CcSEcCtD
Paliperidone—Myalgia—Fluorouracil—skin cancer	0.000404	0.000792	CcSEcCtD
Paliperidone—Decreased appetite—Dactinomycin—skin cancer	0.000404	0.000792	CcSEcCtD
Paliperidone—Fatigue—Dactinomycin—skin cancer	0.000401	0.000785	CcSEcCtD
Paliperidone—Anorexia—Temozolomide—skin cancer	0.000401	0.000785	CcSEcCtD
Paliperidone—Discomfort—Fluorouracil—skin cancer	0.000399	0.000782	CcSEcCtD
Paliperidone—Pain—Dactinomycin—skin cancer	0.000398	0.000779	CcSEcCtD
Paliperidone—Urticaria—Bleomycin—skin cancer	0.000396	0.000776	CcSEcCtD
Paliperidone—Rhinitis—Docetaxel—skin cancer	0.000395	0.000773	CcSEcCtD
Paliperidone—Body temperature increased—Bleomycin—skin cancer	0.000394	0.000772	CcSEcCtD
Paliperidone—Hypoaesthesia—Docetaxel—skin cancer	0.000392	0.000767	CcSEcCtD
Paliperidone—Confusional state—Fluorouracil—skin cancer	0.000391	0.000765	CcSEcCtD
Paliperidone—Urinary tract disorder—Docetaxel—skin cancer	0.000389	0.000762	CcSEcCtD
Paliperidone—Oedema peripheral—Docetaxel—skin cancer	0.000388	0.00076	CcSEcCtD
Paliperidone—Oedema—Fluorouracil—skin cancer	0.000387	0.000759	CcSEcCtD
Paliperidone—Anaphylactic shock—Fluorouracil—skin cancer	0.000387	0.000759	CcSEcCtD
Paliperidone—Connective tissue disorder—Docetaxel—skin cancer	0.000387	0.000758	CcSEcCtD
Paliperidone—Urethral disorder—Docetaxel—skin cancer	0.000386	0.000756	CcSEcCtD
Paliperidone—Infection—Fluorouracil—skin cancer	0.000385	0.000754	CcSEcCtD
Paliperidone—HRH1—lymph node—skin cancer	0.000384	0.00566	CbGeAlD
Paliperidone—Feeling abnormal—Dactinomycin—skin cancer	0.000383	0.000751	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000383	0.000751	CcSEcCtD
Paliperidone—Insomnia—Temozolomide—skin cancer	0.00038	0.000745	CcSEcCtD
Paliperidone—Gastrointestinal pain—Dactinomycin—skin cancer	0.00038	0.000745	CcSEcCtD
Paliperidone—Nervous system disorder—Fluorouracil—skin cancer	0.00038	0.000745	CcSEcCtD
Paliperidone—Thrombocytopenia—Fluorouracil—skin cancer	0.000379	0.000743	CcSEcCtD
Paliperidone—Tachycardia—Fluorouracil—skin cancer	0.000378	0.000741	CcSEcCtD
Paliperidone—Paraesthesia—Temozolomide—skin cancer	0.000378	0.00074	CcSEcCtD
Paliperidone—ADRA2A—lymph node—skin cancer	0.000377	0.00556	CbGeAlD
Paliperidone—Dyspnoea—Temozolomide—skin cancer	0.000375	0.000735	CcSEcCtD
Paliperidone—Somnolence—Temozolomide—skin cancer	0.000374	0.000733	CcSEcCtD
Paliperidone—Dyspepsia—Temozolomide—skin cancer	0.00037	0.000725	CcSEcCtD
Paliperidone—Anorexia—Fluorouracil—skin cancer	0.000369	0.000724	CcSEcCtD
Paliperidone—Eye disorder—Docetaxel—skin cancer	0.000368	0.000721	CcSEcCtD
Paliperidone—Body temperature increased—Dactinomycin—skin cancer	0.000368	0.00072	CcSEcCtD
Paliperidone—Abdominal pain—Dactinomycin—skin cancer	0.000368	0.00072	CcSEcCtD
Paliperidone—Hypersensitivity—Bleomycin—skin cancer	0.000367	0.00072	CcSEcCtD
Paliperidone—Decreased appetite—Temozolomide—skin cancer	0.000366	0.000716	CcSEcCtD
Paliperidone—Cardiac disorder—Docetaxel—skin cancer	0.000365	0.000716	CcSEcCtD
Paliperidone—Flushing—Docetaxel—skin cancer	0.000365	0.000716	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000363	0.000711	CcSEcCtD
Paliperidone—Fatigue—Temozolomide—skin cancer	0.000363	0.00071	CcSEcCtD
Paliperidone—Hypotension—Fluorouracil—skin cancer	0.000362	0.000709	CcSEcCtD
Paliperidone—Constipation—Temozolomide—skin cancer	0.00036	0.000705	CcSEcCtD
Paliperidone—Pain—Temozolomide—skin cancer	0.00036	0.000705	CcSEcCtD
Paliperidone—Asthenia—Bleomycin—skin cancer	0.000358	0.000701	CcSEcCtD
Paliperidone—Angiopathy—Docetaxel—skin cancer	0.000357	0.0007	CcSEcCtD
Paliperidone—Immune system disorder—Docetaxel—skin cancer	0.000356	0.000697	CcSEcCtD
Paliperidone—Mediastinal disorder—Docetaxel—skin cancer	0.000355	0.000695	CcSEcCtD
Paliperidone—Chills—Docetaxel—skin cancer	0.000353	0.000692	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000353	0.000692	CcSEcCtD
Paliperidone—Pruritus—Bleomycin—skin cancer	0.000353	0.000691	CcSEcCtD
Paliperidone—Insomnia—Fluorouracil—skin cancer	0.00035	0.000687	CcSEcCtD
Paliperidone—Paraesthesia—Fluorouracil—skin cancer	0.000348	0.000682	CcSEcCtD
Paliperidone—Alopecia—Docetaxel—skin cancer	0.000348	0.000682	CcSEcCtD
Paliperidone—Feeling abnormal—Temozolomide—skin cancer	0.000347	0.000679	CcSEcCtD
Paliperidone—Dyspnoea—Fluorouracil—skin cancer	0.000345	0.000677	CcSEcCtD
Paliperidone—Mental disorder—Docetaxel—skin cancer	0.000345	0.000676	CcSEcCtD
Paliperidone—Somnolence—Fluorouracil—skin cancer	0.000344	0.000675	CcSEcCtD
Paliperidone—Gastrointestinal pain—Temozolomide—skin cancer	0.000344	0.000674	CcSEcCtD
Paliperidone—Malnutrition—Docetaxel—skin cancer	0.000343	0.000671	CcSEcCtD
Paliperidone—Erythema—Docetaxel—skin cancer	0.000343	0.000671	CcSEcCtD
Paliperidone—Hypersensitivity—Dactinomycin—skin cancer	0.000343	0.000671	CcSEcCtD
Paliperidone—Dyspepsia—Fluorouracil—skin cancer	0.000341	0.000668	CcSEcCtD
Paliperidone—Decreased appetite—Fluorouracil—skin cancer	0.000337	0.00066	CcSEcCtD
Paliperidone—Dysgeusia—Docetaxel—skin cancer	0.000336	0.000657	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000334	0.000655	CcSEcCtD
Paliperidone—Urticaria—Temozolomide—skin cancer	0.000334	0.000655	CcSEcCtD
Paliperidone—Asthenia—Dactinomycin—skin cancer	0.000334	0.000654	CcSEcCtD
Paliperidone—Body temperature increased—Temozolomide—skin cancer	0.000332	0.000651	CcSEcCtD
Paliperidone—Abdominal pain—Temozolomide—skin cancer	0.000332	0.000651	CcSEcCtD
Paliperidone—Back pain—Docetaxel—skin cancer	0.000331	0.000649	CcSEcCtD
Paliperidone—Pain—Fluorouracil—skin cancer	0.000331	0.000649	CcSEcCtD
Paliperidone—Muscle spasms—Docetaxel—skin cancer	0.000329	0.000646	CcSEcCtD
Paliperidone—Feeling abnormal—Fluorouracil—skin cancer	0.000319	0.000626	CcSEcCtD
Paliperidone—Diarrhoea—Dactinomycin—skin cancer	0.000318	0.000623	CcSEcCtD
Paliperidone—Vomiting—Bleomycin—skin cancer	0.000317	0.000621	CcSEcCtD
Paliperidone—Anaemia—Docetaxel—skin cancer	0.000317	0.000621	CcSEcCtD
Paliperidone—Rash—Bleomycin—skin cancer	0.000314	0.000616	CcSEcCtD
Paliperidone—Dermatitis—Bleomycin—skin cancer	0.000314	0.000615	CcSEcCtD
Paliperidone—Hypersensitivity—Temozolomide—skin cancer	0.00031	0.000607	CcSEcCtD
Paliperidone—Urticaria—Fluorouracil—skin cancer	0.000308	0.000603	CcSEcCtD
Paliperidone—Syncope—Docetaxel—skin cancer	0.000307	0.000602	CcSEcCtD
Paliperidone—Leukopenia—Docetaxel—skin cancer	0.000307	0.000601	CcSEcCtD
Paliperidone—Body temperature increased—Fluorouracil—skin cancer	0.000306	0.0006	CcSEcCtD
Paliperidone—Palpitations—Docetaxel—skin cancer	0.000303	0.000593	CcSEcCtD
Paliperidone—Asthenia—Temozolomide—skin cancer	0.000302	0.000591	CcSEcCtD
Paliperidone—Loss of consciousness—Docetaxel—skin cancer	0.000301	0.00059	CcSEcCtD
Paliperidone—Cough—Docetaxel—skin cancer	0.000299	0.000586	CcSEcCtD
Paliperidone—Pruritus—Temozolomide—skin cancer	0.000297	0.000583	CcSEcCtD
Paliperidone—Convulsion—Docetaxel—skin cancer	0.000297	0.000582	CcSEcCtD
Paliperidone—Nausea—Bleomycin—skin cancer	0.000296	0.00058	CcSEcCtD
Paliperidone—Hypertension—Docetaxel—skin cancer	0.000296	0.00058	CcSEcCtD
Paliperidone—Vomiting—Dactinomycin—skin cancer	0.000296	0.000579	CcSEcCtD
Paliperidone—Rash—Dactinomycin—skin cancer	0.000293	0.000574	CcSEcCtD
Paliperidone—Myalgia—Docetaxel—skin cancer	0.000292	0.000572	CcSEcCtD
Paliperidone—Chest pain—Docetaxel—skin cancer	0.000292	0.000572	CcSEcCtD
Paliperidone—Arthralgia—Docetaxel—skin cancer	0.000292	0.000572	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00029	0.000568	CcSEcCtD
Paliperidone—Diarrhoea—Temozolomide—skin cancer	0.000288	0.000564	CcSEcCtD
Paliperidone—Hypersensitivity—Fluorouracil—skin cancer	0.000285	0.000559	CcSEcCtD
Paliperidone—Dry mouth—Docetaxel—skin cancer	0.000285	0.000559	CcSEcCtD
Paliperidone—Confusional state—Docetaxel—skin cancer	0.000282	0.000553	CcSEcCtD
Paliperidone—Oedema—Docetaxel—skin cancer	0.00028	0.000548	CcSEcCtD
Paliperidone—Anaphylactic shock—Docetaxel—skin cancer	0.00028	0.000548	CcSEcCtD
Paliperidone—Dizziness—Temozolomide—skin cancer	0.000278	0.000545	CcSEcCtD
Paliperidone—Infection—Docetaxel—skin cancer	0.000278	0.000544	CcSEcCtD
Paliperidone—Nausea—Dactinomycin—skin cancer	0.000276	0.000541	CcSEcCtD
Paliperidone—Shock—Docetaxel—skin cancer	0.000275	0.000539	CcSEcCtD
Paliperidone—Nervous system disorder—Docetaxel—skin cancer	0.000274	0.000537	CcSEcCtD
Paliperidone—Pruritus—Fluorouracil—skin cancer	0.000274	0.000537	CcSEcCtD
Paliperidone—Thrombocytopenia—Docetaxel—skin cancer	0.000274	0.000537	CcSEcCtD
Paliperidone—Tachycardia—Docetaxel—skin cancer	0.000273	0.000535	CcSEcCtD
Paliperidone—Skin disorder—Docetaxel—skin cancer	0.000272	0.000532	CcSEcCtD
Paliperidone—Vomiting—Temozolomide—skin cancer	0.000267	0.000524	CcSEcCtD
Paliperidone—Anorexia—Docetaxel—skin cancer	0.000267	0.000522	CcSEcCtD
Paliperidone—Rash—Temozolomide—skin cancer	0.000265	0.00052	CcSEcCtD
Paliperidone—Diarrhoea—Fluorouracil—skin cancer	0.000265	0.000519	CcSEcCtD
Paliperidone—Dermatitis—Temozolomide—skin cancer	0.000265	0.000519	CcSEcCtD
Paliperidone—Headache—Temozolomide—skin cancer	0.000263	0.000516	CcSEcCtD
Paliperidone—Hypotension—Docetaxel—skin cancer	0.000261	0.000512	CcSEcCtD
Paliperidone—Dizziness—Fluorouracil—skin cancer	0.000256	0.000502	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000255	0.000499	CcSEcCtD
Paliperidone—Insomnia—Docetaxel—skin cancer	0.000253	0.000496	CcSEcCtD
Paliperidone—Paraesthesia—Docetaxel—skin cancer	0.000251	0.000492	CcSEcCtD
Paliperidone—Nausea—Temozolomide—skin cancer	0.00025	0.000489	CcSEcCtD
Paliperidone—Dyspnoea—Docetaxel—skin cancer	0.000249	0.000489	CcSEcCtD
Paliperidone—Somnolence—Docetaxel—skin cancer	0.000249	0.000487	CcSEcCtD
Paliperidone—Vomiting—Fluorouracil—skin cancer	0.000246	0.000483	CcSEcCtD
Paliperidone—Dyspepsia—Docetaxel—skin cancer	0.000246	0.000482	CcSEcCtD
Paliperidone—Rash—Fluorouracil—skin cancer	0.000244	0.000479	CcSEcCtD
Paliperidone—Dermatitis—Fluorouracil—skin cancer	0.000244	0.000478	CcSEcCtD
Paliperidone—Decreased appetite—Docetaxel—skin cancer	0.000243	0.000476	CcSEcCtD
Paliperidone—Headache—Fluorouracil—skin cancer	0.000243	0.000476	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Docetaxel—skin cancer	0.000241	0.000473	CcSEcCtD
Paliperidone—Fatigue—Docetaxel—skin cancer	0.000241	0.000472	CcSEcCtD
Paliperidone—Pain—Docetaxel—skin cancer	0.000239	0.000469	CcSEcCtD
Paliperidone—Constipation—Docetaxel—skin cancer	0.000239	0.000469	CcSEcCtD
Paliperidone—Feeling abnormal—Docetaxel—skin cancer	0.00023	0.000452	CcSEcCtD
Paliperidone—Nausea—Fluorouracil—skin cancer	0.00023	0.000451	CcSEcCtD
Paliperidone—Gastrointestinal pain—Docetaxel—skin cancer	0.000229	0.000448	CcSEcCtD
Paliperidone—Abdominal pain—Docetaxel—skin cancer	0.000221	0.000433	CcSEcCtD
Paliperidone—Body temperature increased—Docetaxel—skin cancer	0.000221	0.000433	CcSEcCtD
Paliperidone—Hypersensitivity—Docetaxel—skin cancer	0.000206	0.000404	CcSEcCtD
Paliperidone—Asthenia—Docetaxel—skin cancer	0.000201	0.000393	CcSEcCtD
Paliperidone—Pruritus—Docetaxel—skin cancer	0.000198	0.000388	CcSEcCtD
Paliperidone—Diarrhoea—Docetaxel—skin cancer	0.000191	0.000375	CcSEcCtD
Paliperidone—Dizziness—Docetaxel—skin cancer	0.000185	0.000362	CcSEcCtD
Paliperidone—Vomiting—Docetaxel—skin cancer	0.000178	0.000348	CcSEcCtD
Paliperidone—Rash—Docetaxel—skin cancer	0.000176	0.000345	CcSEcCtD
Paliperidone—Dermatitis—Docetaxel—skin cancer	0.000176	0.000345	CcSEcCtD
Paliperidone—Headache—Docetaxel—skin cancer	0.000175	0.000343	CcSEcCtD
Paliperidone—Nausea—Docetaxel—skin cancer	0.000166	0.000325	CcSEcCtD
Paliperidone—ADRA2C—Signaling Pathways—RASA1—skin cancer	1.79e-05	0.000631	CbGpPWpGaD
Paliperidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.78e-05	0.000629	CbGpPWpGaD
Paliperidone—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.78e-05	0.000628	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PTGER4—skin cancer	1.78e-05	0.000628	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SHH—skin cancer	1.77e-05	0.000625	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PTCH1—skin cancer	1.76e-05	0.000622	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—FOXO4—skin cancer	1.76e-05	0.000622	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SMO—skin cancer	1.76e-05	0.000622	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RASA1—skin cancer	1.76e-05	0.000621	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PTCH1—skin cancer	1.75e-05	0.000619	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SMO—skin cancer	1.75e-05	0.000619	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—ENO2—skin cancer	1.75e-05	0.000617	CbGpPWpGaD
Paliperidone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.75e-05	0.000616	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—FOXO4—skin cancer	1.74e-05	0.000614	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PTGER4—skin cancer	1.72e-05	0.000606	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PTGER4—skin cancer	1.71e-05	0.000603	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SMO—skin cancer	1.71e-05	0.000602	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PTCH1—skin cancer	1.71e-05	0.000602	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTCH1—skin cancer	1.68e-05	0.000593	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SMO—skin cancer	1.68e-05	0.000593	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CSPG4—skin cancer	1.67e-05	0.000591	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PTGER4—skin cancer	1.66e-05	0.000586	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTGER4—skin cancer	1.63e-05	0.000577	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SHH—skin cancer	1.63e-05	0.000576	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RASA1—skin cancer	1.62e-05	0.000573	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SHH—skin cancer	1.61e-05	0.000567	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SHH—skin cancer	1.6e-05	0.000566	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—ENO2—skin cancer	1.6e-05	0.000565	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RASA1—skin cancer	1.6e-05	0.000564	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RASA1—skin cancer	1.59e-05	0.000562	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SHH—skin cancer	1.57e-05	0.000555	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—FOXO4—skin cancer	1.57e-05	0.000554	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RASA1—skin cancer	1.56e-05	0.000552	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTCH1—skin cancer	1.55e-05	0.000546	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SMO—skin cancer	1.55e-05	0.000546	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—NRAS—skin cancer	1.54e-05	0.000544	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTCH1—skin cancer	1.52e-05	0.000538	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SMO—skin cancer	1.52e-05	0.000538	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SMO—skin cancer	1.52e-05	0.000536	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTCH1—skin cancer	1.52e-05	0.000536	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—FOXO4—skin cancer	1.52e-05	0.000535	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—FOXO4—skin cancer	1.51e-05	0.000532	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTGER4—skin cancer	1.51e-05	0.000532	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTCH1—skin cancer	1.49e-05	0.000526	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SMO—skin cancer	1.49e-05	0.000526	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTGER4—skin cancer	1.48e-05	0.000523	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTGER4—skin cancer	1.48e-05	0.000522	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—FOXO4—skin cancer	1.47e-05	0.000518	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SHH—skin cancer	1.46e-05	0.000516	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RASA1—skin cancer	1.45e-05	0.000513	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTGER4—skin cancer	1.45e-05	0.000512	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—FOXO4—skin cancer	1.44e-05	0.00051	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—NRAS—skin cancer	1.44e-05	0.000508	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTCH1—skin cancer	1.39e-05	0.000489	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SMO—skin cancer	1.39e-05	0.000489	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PLIN2—skin cancer	1.36e-05	0.00048	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TERT—skin cancer	1.36e-05	0.000479	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTGER4—skin cancer	1.35e-05	0.000476	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—FOXO4—skin cancer	1.33e-05	0.00047	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TERT—skin cancer	1.33e-05	0.000469	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—KRAS—skin cancer	1.32e-05	0.000468	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—FOXO4—skin cancer	1.31e-05	0.000462	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TERT—skin cancer	1.31e-05	0.000462	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—FOXO4—skin cancer	1.31e-05	0.000461	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—FOXO4—skin cancer	1.28e-05	0.000453	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—ERCC2—skin cancer	1.25e-05	0.000441	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—KRAS—skin cancer	1.24e-05	0.000437	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—FOXO4—skin cancer	1.19e-05	0.000421	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—TP53—skin cancer	1.18e-05	0.000416	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TERT—skin cancer	1.18e-05	0.000416	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—NRAS—skin cancer	1.17e-05	0.000412	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TERT—skin cancer	1.16e-05	0.00041	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—NRAS—skin cancer	1.14e-05	0.000404	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ENO2—skin cancer	1.14e-05	0.000402	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—HRAS—skin cancer	1.13e-05	0.000398	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—NRAS—skin cancer	1.12e-05	0.000395	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—NRAS—skin cancer	1.1e-05	0.000389	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—TP53—skin cancer	1.1e-05	0.000388	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CSPG4—skin cancer	1.1e-05	0.000387	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—BRAF—skin cancer	1.07e-05	0.000379	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—BRAF—skin cancer	1.05e-05	0.000372	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—HRAS—skin cancer	1.05e-05	0.000371	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TERT—skin cancer	1.05e-05	0.00037	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—BRAF—skin cancer	1.04e-05	0.000366	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—ERCC2—skin cancer	1.01e-05	0.000358	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TERT—skin cancer	1.01e-05	0.000357	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TERT—skin cancer	1.01e-05	0.000356	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—KRAS—skin cancer	1.01e-05	0.000355	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—NRAS—skin cancer	9.92e-06	0.00035	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—KRAS—skin cancer	9.84e-06	0.000347	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TERT—skin cancer	9.79e-06	0.000346	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—NRAS—skin cancer	9.78e-06	0.000346	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TERT—skin cancer	9.64e-06	0.00034	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—KRAS—skin cancer	9.63e-06	0.00034	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—KRAS—skin cancer	9.48e-06	0.000335	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—BRAF—skin cancer	9.32e-06	0.000329	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—ERCC2—skin cancer	9.3e-06	0.000328	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—BRAF—skin cancer	9.2e-06	0.000325	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—TP53—skin cancer	8.93e-06	0.000315	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TERT—skin cancer	8.89e-06	0.000314	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—NRAS—skin cancer	8.83e-06	0.000312	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TERT—skin cancer	8.74e-06	0.000309	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TERT—skin cancer	8.72e-06	0.000308	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TERT—skin cancer	8.56e-06	0.000302	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—HRAS—skin cancer	8.54e-06	0.000302	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—KRAS—skin cancer	8.53e-06	0.000301	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—NRAS—skin cancer	8.53e-06	0.000301	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—NRAS—skin cancer	8.48e-06	0.0003	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—KRAS—skin cancer	8.42e-06	0.000297	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—HRAS—skin cancer	8.36e-06	0.000295	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—BRAF—skin cancer	8.3e-06	0.000293	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—NRAS—skin cancer	8.25e-06	0.000291	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—HRAS—skin cancer	8.19e-06	0.000289	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—NRAS—skin cancer	8.12e-06	0.000287	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—HRAS—skin cancer	8.06e-06	0.000285	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—BRAF—skin cancer	8.02e-06	0.000283	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—IL6—skin cancer	8e-06	0.000283	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—BRAF—skin cancer	7.97e-06	0.000282	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TERT—skin cancer	7.95e-06	0.000281	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—IL6—skin cancer	7.84e-06	0.000277	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—BRAF—skin cancer	7.76e-06	0.000274	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—IL6—skin cancer	7.71e-06	0.000272	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—BRAF—skin cancer	7.63e-06	0.00027	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—KRAS—skin cancer	7.6e-06	0.000268	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PTGS2—skin cancer	7.49e-06	0.000265	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—NRAS—skin cancer	7.49e-06	0.000264	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ENO2—skin cancer	7.44e-06	0.000263	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—NRAS—skin cancer	7.37e-06	0.00026	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—NRAS—skin cancer	7.35e-06	0.00026	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—KRAS—skin cancer	7.34e-06	0.000259	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—KRAS—skin cancer	7.3e-06	0.000258	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—HRAS—skin cancer	7.25e-06	0.000256	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—NRAS—skin cancer	7.21e-06	0.000255	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—HRAS—skin cancer	7.16e-06	0.000253	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—KRAS—skin cancer	7.1e-06	0.000251	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—BRAF—skin cancer	7.04e-06	0.000249	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—KRAS—skin cancer	6.99e-06	0.000247	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—IL6—skin cancer	6.94e-06	0.000245	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—BRAF—skin cancer	6.92e-06	0.000245	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—BRAF—skin cancer	6.91e-06	0.000244	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—IL6—skin cancer	6.85e-06	0.000242	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—BRAF—skin cancer	6.78e-06	0.000239	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—NRAS—skin cancer	6.75e-06	0.000238	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—NRAS—skin cancer	6.7e-06	0.000237	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ERCC2—skin cancer	6.61e-06	0.000234	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—NRAS—skin cancer	6.61e-06	0.000234	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—NRAS—skin cancer	6.51e-06	0.00023	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—HRAS—skin cancer	6.46e-06	0.000228	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—KRAS—skin cancer	6.44e-06	0.000228	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—KRAS—skin cancer	6.34e-06	0.000224	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—KRAS—skin cancer	6.33e-06	0.000223	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—BRAF—skin cancer	6.3e-06	0.000222	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—HRAS—skin cancer	6.24e-06	0.00022	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—KRAS—skin cancer	6.21e-06	0.000219	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—HRAS—skin cancer	6.21e-06	0.000219	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—IL6—skin cancer	6.19e-06	0.000218	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—skin cancer	6.09e-06	0.000215	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—HRAS—skin cancer	6.04e-06	0.000213	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—IL6—skin cancer	5.97e-06	0.000211	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—HRAS—skin cancer	5.94e-06	0.00021	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—IL6—skin cancer	5.94e-06	0.00021	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—NRAS—skin cancer	5.86e-06	0.000207	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—KRAS—skin cancer	5.81e-06	0.000205	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—NRAS—skin cancer	5.78e-06	0.000204	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—IL6—skin cancer	5.78e-06	0.000204	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—KRAS—skin cancer	5.77e-06	0.000204	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—KRAS—skin cancer	5.69e-06	0.000201	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—IL6—skin cancer	5.69e-06	0.000201	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—KRAS—skin cancer	5.6e-06	0.000198	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—skin cancer	5.58e-06	0.000197	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—HRAS—skin cancer	5.48e-06	0.000193	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—HRAS—skin cancer	5.39e-06	0.00019	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HRAS—skin cancer	5.38e-06	0.00019	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—skin cancer	5.28e-06	0.000186	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—skin cancer	5.24e-06	0.000185	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NRAS—skin cancer	5.22e-06	0.000184	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—skin cancer	5.17e-06	0.000182	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—skin cancer	5.16e-06	0.000182	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—skin cancer	5.15e-06	0.000182	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—skin cancer	5.06e-06	0.000179	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—skin cancer	5.05e-06	0.000178	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—skin cancer	5.04e-06	0.000178	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRAS—skin cancer	5.04e-06	0.000178	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRAS—skin cancer	5.01e-06	0.000177	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—skin cancer	4.98e-06	0.000176	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—skin cancer	4.97e-06	0.000176	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—skin cancer	4.94e-06	0.000174	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—skin cancer	4.9e-06	0.000173	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRAS—skin cancer	4.87e-06	0.000172	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—skin cancer	4.84e-06	0.000171	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRAS—skin cancer	4.8e-06	0.000169	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—skin cancer	4.76e-06	0.000168	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—skin cancer	4.73e-06	0.000167	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—skin cancer	4.69e-06	0.000166	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—skin cancer	4.63e-06	0.000164	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—skin cancer	4.56e-06	0.000161	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—skin cancer	4.49e-06	0.000159	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—skin cancer	4.48e-06	0.000158	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRAS—skin cancer	4.42e-06	0.000156	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—skin cancer	4.42e-06	0.000156	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRAS—skin cancer	4.35e-06	0.000154	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRAS—skin cancer	4.34e-06	0.000153	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—skin cancer	4.34e-06	0.000153	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ERCC2—skin cancer	4.32e-06	0.000153	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—skin cancer	4.31e-06	0.000152	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—skin cancer	4.29e-06	0.000151	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRAS—skin cancer	4.26e-06	0.00015	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—skin cancer	4.23e-06	0.000149	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—skin cancer	4.2e-06	0.000148	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—skin cancer	4.13e-06	0.000146	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—skin cancer	4.1e-06	0.000145	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—skin cancer	4.05e-06	0.000143	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—skin cancer	3.99e-06	0.000141	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—skin cancer	3.97e-06	0.00014	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRAS—skin cancer	3.96e-06	0.00014	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—skin cancer	3.85e-06	0.000136	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—skin cancer	3.83e-06	0.000135	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—skin cancer	3.82e-06	0.000135	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—skin cancer	3.81e-06	0.000134	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—skin cancer	3.75e-06	0.000132	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—skin cancer	3.74e-06	0.000132	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—skin cancer	3.73e-06	0.000132	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—skin cancer	3.69e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—skin cancer	3.67e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—skin cancer	3.67e-06	0.00013	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—skin cancer	3.67e-06	0.000129	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—skin cancer	3.65e-06	0.000129	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—skin cancer	3.57e-06	0.000126	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—skin cancer	3.53e-06	0.000125	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—skin cancer	3.51e-06	0.000124	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—skin cancer	3.51e-06	0.000124	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—skin cancer	3.41e-06	0.000121	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—skin cancer	3.41e-06	0.00012	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—skin cancer	3.38e-06	0.000119	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—skin cancer	3.36e-06	0.000119	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—skin cancer	3.33e-06	0.000118	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—skin cancer	3.32e-06	0.000117	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—skin cancer	3.26e-06	0.000115	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—skin cancer	3.24e-06	0.000114	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—skin cancer	3.18e-06	0.000112	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—skin cancer	3.18e-06	0.000112	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—skin cancer	3.12e-06	0.00011	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—skin cancer	3.1e-06	0.000109	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—skin cancer	3.05e-06	0.000108	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—skin cancer	3.04e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—skin cancer	3.03e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—skin cancer	2.98e-06	0.000105	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—skin cancer	2.9e-06	0.000102	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—skin cancer	2.77e-06	9.79e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—skin cancer	2.59e-06	9.16e-05	CbGpPWpGaD
